近一年净值增长超60%，上银医疗健康混合A荣获三年期五星评级

Core Viewpoint - The pharmaceutical sector is experiencing significant investor interest, particularly in innovative drugs, with the CSI Innovation Drug 30 Index rising over 43% year-to-date as of August 15 [1] Group 1: Fund Performance - The Shangyin Medical Health Mixed A Fund (code: 011288) has effectively captured opportunities in innovative drugs, achieving a five-star rating from Guotai Junan Securities as of the end of July [1] - As of July 31, the fund ranked in the top 8% for one-year performance among its peers, with a net value growth rate of 61.44%, significantly outperforming the benchmark return of 23.88% [1] - Over a three-year period, the fund also demonstrated strong competitive advantages, ranking in the top 7% for performance and top 5% for excess returns among its peers [1] Group 2: Manager's Background - The fund manager, Yang Jiannan, has a unique combination of expertise with a background in biomedical engineering and a master's degree in industrial economics, along with frontline experience in the biotechnology industry [2] - Yang's cross-disciplinary skills in biomedical research, industry practice, and financial investment are rare in the market, contributing to a strong research capability and value discovery [2] Group 3: Industry Outlook - The pharmaceutical and biotechnology sector has shown a recovery this year, with the Shenwan Pharmaceutical and Biotechnology Index rising over 25%, ranking fourth among 31 Shenwan primary industries [2] - Yang believes the current innovative drug market is not a temporary trend but has a solid long-term upward foundation, indicating a significant transformation in the pharmaceutical industry [2] - The industry is on the verge of a shift from traditional pharmaceuticals to more specific drugs, likened to a transition from "carriages" to "automobiles" [2] Group 4: Investment Strategy - Yang emphasizes the importance of leveraging China's advantages in innovative drug development, focusing on low-cost and efficient development of better products [2] - The investment strategy primarily targets leading players in specific innovation trends, closely monitoring clinical data and progress to mitigate the risks of research failures [2]